|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2003-12-3
|
|
pubmed:abstractText |
Antagonists of the integrin receptor alpha(v)beta(3) are expected to have utility in the treatment of osteoporosis through inhibition of bone resorption. A series of potent, chain-shortened, pyrrolidinone-containing alpha(v)beta(3) receptor antagonists is described. Two sets of diasteromeric pairs of high-affinity antagonists demonstrated marked differences in log P values, which translated into differing dog pharmacokinetic properties. One member of this set was demonstrated to be effective in reducing bone resorption in rats.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:DugganMark EME,
pubmed-author:DuongL TLT,
pubmed-author:Fernandez-MetzlerCarmenC,
pubmed-author:HartmanGeorge DGD,
pubmed-author:KimmelDonald BDB,
pubmed-author:LeuChih TaiCT,
pubmed-author:LynchJoseph JJJ,
pubmed-author:MeissnerRobert SRS,
pubmed-author:PerkinsJames JJJ,
pubmed-author:PrueksaritanontThomayantT,
pubmed-author:RodanGideon AGA,
pubmed-author:RodanSevgi BSB
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4285-8
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA.
|
|
pubmed:publicationType |
Journal Article
|
